Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Perspective Therapeutics Logo
Perspective Therapeutics Growth Score
72
CB Rank
14819
Heat Score
68
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Founded
obfuscation
PublicPost-IPO Equity Seattle, Washington, United States101-250 perspectivetherapeutics.com/
Health Care
Medical
Therapeutics
Overview

Perspective Therapeutics
Total Funding
obfuscation
Growth Score
72
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score72
-8 pts
in past quarter
Heat Score 68
-13 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Perspective Therapeutics

CB Rank
14819
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Founded
obfuscation
PublicPost-IPO Equity Seattle, Washington, United States101-250 perspectivetherapeutics.com/
Health Care
Medical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Thijs Spoor
    Thijs Spoor: Chief Executive Officer
    Past Role: Viewpoint Molecular Targeting, Chief Executive Officer
  • Photo of Joel Sendek
    Joel Sendek: Chief Financial Officer
    Past Role: Dewpoint Therapeutics, Chief Financial Officer

Details

Legal Name Perspective Therapeutics, Inc
Also Known As Isoray
Operating Status Active
Stock Symbol  NYSEMKT:CATX
Company Type For Profit
About the Company
Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them.
Phone Number +1 (206) 676-0900
Contact Email marketingops@perspectivetherapeutics.com
Predictions & Insights

Growth Insight

See this Growth Insight
Perspective Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Pb-212-based Alpha-Particle Radiotherapies
Radiopharmaceutical therapies using Pb-212 to deliver alpha radiation directly to cancer cells for targeted tumor treatment.
Image-Guided Theranostics Platform
A platform that uses imaging to confirm tumor target expression and distribution before delivering targeted alpha-particle therapy.

Research & Development

Perspective Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Perspective Therapeutics Logo
Post-IPO Equity - Perspective Therapeutics
7
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 2 Board Members and Advisors 1 Contacts 43

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,392
47.86%
 in past month

IT Spend

$25.8KThis year, Perspective Therapeutics is projected to spend $25.8K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Incredibuild Logo
Incredibuild
76
3D Engines Logo
3D Engines
71
Initial Coin Offering (ICO) Logo
Initial Coin Offering (ICO)
—

Actively Used Products

11Perspective Therapeutics uses 11 technology products and services including HTML5, F5 NGINX, and  Google Tag Manager, according to G2 Stack.

Active Website Tech Count

42Perspective Therapeutics is actively using 42 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.
Sub-Organizations
Frequently Asked Questions

Where is Perspective Therapeutics's headquarters? Perspective Therapeutics is located in Seattle, Washington, United States.Who invested in Perspective Therapeutics? Perspective Therapeutics has 8 investors including Surveyor Capital and  Spruce Street Capital.When was the last funding round for Perspective Therapeutics? Perspective Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Perspective Therapeutics's competitors? Alternatives and possible competitors to Perspective Therapeutics may include Eclipse, Aktis Oncology, and  Janux Therapeutics.How much funding has Perspective Therapeutics raised to date? Perspective Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(53d292a 1)
|